Citations

Clear

4802 citation(s) found for "Yu, Jennifer".

528 REM Sleep Without Atonia in Idiopathic REM Sleep Behavior Disorder in the North American Prodromal Synucleinopathy Cohort
Feemster, John, Timm, Paul, Teigen, Luke, Faber, Sarah, Steele, Tyler, Hedtkamp, Kristina, Ju, Yo‐El S. , McCleland, Jennifer, Pelletier, Amélie , Avidan, Alon Y. , Avidan, Alon Y , McCarter, Stuart J. , Boeve, Bradley F. , Postuma, Ronald B. , Bliwise, Donald L. , Louis, Erik K. St.

Mayo Clinic

Sleep | May 3, 2021 | Volume: 44 | Issue: Supplement_2 | Pages: A208-A208

10.1093/sleep/zsab072.527 Get It

Abstract Introduction Idiopathic/isolated REM sleep behavior disorder (iRBD) is a prodromal alpha-synucleinopathy characterized by dream enactment behavior and REM sleep without atonia (RSWA). We sought to define quantitative RSWA diagnostic thresholds in the North American Prodromal Synucleinopathy (NAPS) Consortium cohort. We analyzed RSWA between iRBD patients across participating NAPS sleep centers, compared to normative controls, and hypothesized that previous diagnostic RSWA thresholds were overestimates. Methods All digital polysomnography files were converted to European Data Format and scored at a central laboratory (Mayo Clinic) which standardized display scoring montages, channel sensitivities, and filtering, and scripted computational analyses for visual scoring. RSWA was quantitatively analyzed in the submentalis (SM) and anterior tibialis (AT) muscles in iRBD (n=86) patients and controls (n=118) utilizing well validated visual (Mayo) and automated (RAI) methods. Parametric statistics were used to compare RSWA metrics, and RSWA thresholds were developed using receiver operating characteristic curves. Results RSWA was significantly higher for the RAI and all visual individual and combined muscle activity metrics in iRBD compared to controls (all p<0.001). Average SM phasic measures were: 14.2% (Mayo), 17.9% (McGill), 18.5% (UCLA), and 9.4% (Washington University). Average AT phasic measures at each site were: 26.7% (Mayo), 17.1% (McGill), 23.3% (UCLA), and 17.4% (Washington University). Average SM/AT ‘any’ measures at each site were: 45.4% (Mayo), 35.9% (McGill), 53.4% (UCLA), and 23.5% (Washington University). Overall cohort RBD diagnostic thresholds (AUC, specificity/sensitivity) were: SM phasic 4.9% (90.0, 82.2%/83.7%); AT phasic 7.6% (88.7%, 82.2%/81.4%) and combined SM/AT ‘any’ 13% (94.6, 83.9%/96.5%). Conclusion RSWA thresholds in the NAPS cohort were substantially lower than previously reported, suggesting previously overestimated diagnostic RSWA thresholds due to smaller, enriched patient samples and overfit statistical modeling. Confirmation of these findings in the complete NAPS cohort (n=300 iRBD patients across all 10 NAPS centers) is planned. Support (if any):
The Pitfalls of Using Research Grade Immunoassays for Thyroid Health Measurements
Boggs, Ashley S.P. , Kemp, Jennifer, Ravinder, Singh J, Grebe, Stefan K. , Galligan, Thomas M.

Mayo Clinic

Journal of the Endocrine Society | May 3, 2021 | Volume: 5 | Issue: Supplement_1 | Pages: A834-A834

10.1210/jendso/bvab048.1701 Get It

Abstract Introduction: Immunoassay technology is subject to matrix interferences that can produce inaccurate results and incorrect conclusions when using samples not previously validated. While many commercially available research grade (RG) immunoassay kits are available, caution should be applied when using RG kits for thyroid health assessments, particularly on samples from pregnant individuals whose blood chemistry is unique to non-pregnant individuals. Question: Do RG immunoassay kits reliably provide precise and accurate measurements of thyroid health biomarkers in serum Standard Reference Materials (SRMs) from pregnant and non-pregnant donors? Methods: T4, T3, rT3, Tg and TSH measurements were conducted on SRMs 971, Hormones in Frozen Human Serum, and SRM 1949, Frozen Prenatal Serum, using RG immunoassay kits. When available, performance was assessed against validated FDA approved immunoassays or mass spectrometric (MS) methods. Results: RG kits were variable, inaccurate, or imprecise for four of the six biomarkers assessed. RG kit total thyroid hormone measurements overall performed comparably to MS methods, except rT3 measurements, which were twofold greater than mass spectrometric measurements (971M RG mean = 0.51 ng/mL, MS mean = 0.20 ng/mL, p < 0.0001; 971F RG = 0.48 ng/mL, MS = 0.18 ng/mL, p < 0.0001) and had CVs over 30 %. RG kit Tg measurements varied sometimes by as much as tenfold (971M means of 6.50 ng/mL up to 63.3 ng/mL, p < 0.0001; 971F means of 0.350 ng/mL up to 14.5 mg/mL, p < 0.0001). TSH values differed by RG kit manufacturer (971M means of 1.27 µIU/mL up to 1.82 µIU/mL, p < 0.0001; 971F means of 1.36 µIU/mL up to 2.27 µIU/mL, p < 0.0001) and by dilution scheme using the same manufacturer with one case indicating a diagnosis of hypothyroid versus normal TSH levels (1949 non-pregnant undiluted mean = 2325 pg/mL, half dilution mean = 1631 pg/mL, p < 0.0001). Conclusions: RG immunoassays are often used for research projects because they do not require expensive equipment and are simple to conducted. However, we demonstrate here that not all kits are accurate for all patient samples. By utilizing a matrix matched SRM with well-defined quantities of thyroid health biomarkers, one can assess method accuracy, making measurements from different methods comparable. Thereby, data can be harmonized to contribute reliable data on thyroid biomarkers to advance the field of thyroid health.
Garetosmab Reduces Flare-ups in Patients With Fibrodysplasia Ossificans Progressiva
McGinniss, Jennifer, Mellis, Scott , Sanchez, Robert J., Rocco, Maja Di , Roux, Christian , Kolta, S., Bubbear, Judith , Cheung, Angela M. , Botman, Esmée , Mukaddam, Mona Al , Tile, Lianne, Portal‐Celhay, Cynthia, Sarkar, Neena, Hou, Peijie , Forleo‐Neto, Eduardo , Rankin, A. J., Trotter, Dinko González , Pignolo, Robert J. , Cheung, Angela M , Dahir, Kathryn , Keen, Richard , Orcel, Philippe , Funck‐Brentano, Thomas , Madeo, Annalisa , Tabarkiewicz, Jacek , Szczepanek, Małgorzata, Bachiller‐Corral, Javier , Economides, Aris N. , Eekhoff, Elisabeth M. W. , Kaplan, Frederick S.

Mayo Clinic

Journal of the Endocrine Society | May 3, 2021 | Volume: 5 | Issue: Supplement_1 | Pages: A251-A252

10.1210/jendso/bvab048.512 Get It

Abstract Background: Fibrodysplasia ossificans progressiva (FOP) is an ultra-rare, autosomal dominant disorder driven by mutations in ACVR1 that render it responsive to Activin A. FOP is characterized by progressive heterotopic ossification (HO) and distressing inflammatory events called “flare-ups.” Flare-ups can precede new HO; however, limited prospective data exists on this phenomenon. Garetosmab (GAR), an investigational human monoclonal antibody against Activin A, blocks formation of new HO in FOP. Methods: This is a post-hoc analysis of LUMINA-1 (NCT03188666) a phase 2, randomized, double-blind, placebo-controlled study, which evaluated the safety and efficacy of GAR (10 mg/kg/week IV) versus placebo (PBO) in adult patients with FOP over 28 weeks. Patient-reported flare-ups were collected via a patient diary and severity level was reported as mild, moderate or severe. Clinician-reported flare-ups were collected as adverse events in the trial. HO lesions were imaged by 18F-NaF positron emission tomography (PET) and whole-body low-dose X-ray computed tomography (CT). Results: There was a two-fold higher proportion of patients who reported one or more flare-ups on PBO 17/24 (71%) compared with GAR 7/20 (35%). Clinicians reported a four-fold higher proportion of patients experiencing one or more flare-ups on PBO 10/24 (42%) compared with GAR 2/20 (10%). Overall rates of flare-up events were two-fold higher on PBO vs. GAR (1.4 vs. 0.65 events/patient/28 weeks) for patient-reported events and eight-fold higher on PBO vs. GAR by clinician report (0.83 vs. 0.10 events/patient/28 weeks). Most flare-ups occurred on the extremities and back; pain was the most commonly reported symptom. Patient-reported flare-ups on PBO were more frequently reported as severe (29.4%) compared with GAR (7.7%). Among subjects with at least 12 weeks of follow-up from start of patient-reported flare-up, development of new HO near the site was 5/27 (18.5%) on PBO and (0%) on GAR. Of all new HO lesions, 41% on PBO and 0% on GAR occurred with spatial and temporal relation to flare-up. Conclusions: Approximately two-thirds of patients on PBO reported flare-ups over 28 weeks. GAR was associated with reductions in frequency and severity of flare-ups. Fewer than 20% of patient-reported flare-ups were associated with new HO, indicating frequent discordance of these phenomena, and compatible with previous reports. GAR’s ability to reduce patient- and clinician-reported flare-ups, as well as new HO lesions may provide an important therapeutic option.
Incident Cardiometabolic Outcomes in Adrenal Adenomas: A Population-Based Cohort Study of 1,004 Patients
Zhang, Catherine D , Atkinson, Elizabeth J. , Achenbach, Sara J., Li, Dingfeng , Kaur, Ravinder Jeet , Singh, Sumitabh , Rocca, Walter A. , Ebbehøj, Andreas , Sauver, Jennifer L. St. , Young, William F. , Arlt, Wiebke , Bancos, Irina

Mayo Clinic

Journal of the Endocrine Society | May 3, 2021 | Volume: 5 | Issue: Supplement_1 | Pages: A87-A87

10.1210/jendso/bvab048.174 Get It

Abstract Background: Adrenal adenomas have been linked with cardiovascular morbidity in selected patient populations from specialized referral centers. Population-based data examining the association of adrenal adenomas with cardiometabolic outcomes are lacking. Aim: To determine the incidence of cardiometabolic outcomes in a population-based cohort of patients with adrenal adenomas. Methods: We conducted a population-based cohort study of patients diagnosed with adrenal adenomas while living in a defined community from 1995–2017. Eligible patients were retrospectively identified by a medical records linkage system and confirmed on chart review. Adenomas were classified as mild autonomous cortisol secretion (MACS) if the serum cortisol concentration was >1.8 mcg/dL after 1 mg overnight dexamethasone suppression test (DST), nonfunctioning adrenal tumor (NFAT) if serum cortisol after DST was ≤1.8 mcg/dL, and adenoma with unknown cortisol secretion (AUCS) if DST was not performed. Patients with overt hormone excess were excluded. Cardiometabolic outcomes were assessed at the time of adrenal adenoma diagnosis. Patients were then followed until death, migration out of the community, or through December 31, 2017. Incident outcomes were assessed starting at 1 year following the diagnosis and excluded those with the outcome of interest at baseline, except for myocardial infarction (MI) and coronary intervention, which were adjusted for in the analysis. Results: were compared to 1:1 age and sex-matched referent subjects without adrenal adenomas from the same community. Results: Adrenal adenomas were diagnosed in 1004 patients with 141 (14%) NFAT, 81 (8%) MACS, and 782 (78%) AUCS. The median age of diagnosis was 63 years (range, 20–96), and 582 (58%) were women. The baseline data was previously presented and showed higher prevalence of hypertension, diabetes, peripheral vascular disease (PVD), and heart failure (HF) in the adenoma group, after adjusting for BMI and tobacco use. During a median follow-up of 6.8 years (range, 0–22), patients with adrenal adenomas were more likely than referent subjects to develop new-onset dyslipidemia (HR 1.31, 95% CI 1.03–1.67), diabetes (HR 1.68, 95% CI 1.28–2.22), chronic kidney disease (HR 1.77, 95% CI 1.39–2.25), atrial fibrillation (HR 1.32 (1.03–1.70), PVD (HR 1.61, 95% CI 1.24–2.09), and HF (HR 1.46, 95% CI 1.15–1.85). In addition, the adenoma group had higher risk for incident MI (HR 1.62, 95% CI 1.16–2.25) and coronary intervention (HR 1.70, 95% CI 1.25–2.31). Conclusions: Adrenal adenomas are associated with increased incidence of adverse cardiometabolic outcomes in this population-based cohort study. While these results are potentially explained by different degrees of cortisol excess, the majority of patients received suboptimal hormone evaluation, suggesting a knowledge gap in the workup of adrenal adenomas in the broader medical community.
Clinical Reasoning: A 49-Year-Old Woman With Progressive Numbness and Gait Instability
Zahid, Anza , Shah, Shailee , Martinez‐Thompson, Jennifer M. , Arment, Courtney A. , Huang, Yajue, Dubey, Divyanshu , Dubey, Divyanshu , Shah, Shailee , Sturgis, Charles D.

Mayo Clinic

Neurology | May 1, 2021 | Volume: 97 | Issue: 7 | Pages: 342-347

10.1212/wnl.0000000000012135 | PMID 33931535 Get It

Feasibility of Cell-Free DNA Collection and Clonal Immunoglobulin Sequencing in South African Patients With HIV-Associated Lymphoma
Vogt, Samantha L. , Patel, Moosa , Lakha, Atul , Philip, Vinitha , Omar, Tanvier , Ashmore, Philippa , Pather, Sugeshnee , Haley, Lisa , Zheng, Gang , Mayne, Elizabeth , Stevens, Wendy , Wagner‐Johnston, Nina D. , Gocke, Christopher D. , Martinson, Neil , Ambinder, Richard F. , Xian, Rena R. , Gocke, Christopher D , Ambinder, Richard F , Stone, Jennifer

Mayo Clinic

JCO Global Oncology | April 28, 2021 | Volume: No volume available | Issue: 7 | Pages: 611-621

10.1200/go.20.00651 | PMID 33909482 Get It

PURPOSEDiagnosis of AIDS lymphoma in low-resource settings, like South Africa, is often delayed, leaving patients with limited treatment options. In tuberculosis (TB) endemic regions, overlapping signs and symptoms often lead to diagnostic delays. Assessment of plasma cell-free DNA (cfDNA) by next-generation sequencing (NGS) may expedite the diagnosis of lymphoma but requires high-quality cfDNA.METHODSPeople living with HIV with newly diagnosed aggressive B-cell lymphoma and those with newly diagnosed TB seeking care at Chris Hani Baragwanath Academic Hospital and its surrounding clinics, in Soweto, South Africa, were enrolled in this study. Each participant provided a whole blood specimen collected in cell-stabilizing tubes. Quantity and quality of plasma cfDNA were assessed. NGS of the immunoglobulin heavy chain was performed.RESULTSNine HIV+ patients with untreated lymphoma and eight HIV+ patients with TB, but without lymphoma, were enrolled. All cfDNA quantity and quality metrics were similar between the two groups, except that cfDNA accounted for a larger fraction of recovered plasma DNA in patients with lymphoma. The concentration of cfDNA in plasma also trended higher in patients with lymphoma. NGS of immunoglobulin heavy chain showed robust amplification of DNA, with large amplicons (> 250 bp) being more readily detected in patients with lymphoma. Clonal sequences were detected in five of nine patients with lymphoma, and none of the patients with TB.CONCLUSIONThis proof-of-principle study demonstrates that whole blood collected for cfDNA in a low-resource setting is suitable for sophisticated sequencing analyses, including clonal immunoglobulin NGS. The detection of clonal sequences in more than half of patients with lymphoma shows promise as a diagnostic marker that may be explored in future studies.
Underlying pathology identified after 20 years of disease course in two cases of slowly progressive frontotemporal dementia syndromes
Hokelekli, Fatma Ozlem , Whitwell, Jennifer L. , Uitti, Ryan J. , Pham, Nha Trang Thu, Lowe, Val J. , Josephs, Keith A. , Machulda, Mary M. , Jones, David T. , Giannini, Caterina , Baker, Matthew , Dickson, Dennis W.

Mayo Clinic

Neurocase | April 27, 2021 | Volume: 27 | Issue: 2 | Pages: 212-222

10.1080/13554794.2021.1918723 | PMID 33904372 Get It

Feasibility of a Health Coaching and Home-Based Rehabilitation Intervention With Remote Monitoring for COPD
Benzo, Roberto P. , Ridgeway, Jennifer L. , Hoult, Johanna, Novotny, Paul J. , Thomas, B.E., Lam, Nyanjok M, Benzo, M.V. , Kramer, K. , Seifert, Sara J. , Ridgeway, Jennifer, Hoult, Johanna P, Novotny, Paul, Thomas, Benjamin E, V Benzo, Maria, Ridgeway, Jennifer L

Mayo Clinic

Respiratory Care | April 27, 2021 | Volume: 66 | Issue: 6 | Pages: 960-971

10.4187/respcare.08580 | PMID 33906954 Get It

BACKGROUND: Pulmonary rehabilitation is an effective treatment for patients with COPD, but patient uptake and adherence to the current offering of center-based pulmonary rehabilitation is modest due to transportation, access, poverty, and frailty, and even more so in the context of the COVID pandemic. Home-based options have been proposed and were found noninferior to center-based rehabilitation; however, there is a lack of home-based programs, and more understanding is needed. We aimed to test the feasibility, uptake, and adherence to a home-based program for COPD rehabilitation with health coaching. METHODS: We conducted a randomized trial with a wait-list controlled design to evaluate the effects of a home-based program with health coaching on breathlessness in subjects with moderate to severe COPD unable to attend the regular pulmonary rehabilitation program. The 8-week intervention consisted of video-guided exercises to be done 6 times a week and captured with a computer tablet. Health coaching was done weekly over the telephone to review subject activity and symptoms and to provide an opportunity for the subject to define their weekly goals. The primary outcomes were uptake, adherence, and Chronic Respiratory Questionnaire (CRQ) Dyspnea Domain. Secondary outcomes were self-management abilities and CRQ Emotions-Mastery-Fatigue. RESULTS: 154 subjects with moderate to severe COPD were randomized. Subject adherence was 86% to the proposed 6-times a week exercise routine. There ( P = .062) was no significant difference in breathlessness (CRQ dyspnea). There was a significant improvement in self-management abilities ( P < .001). The results of the qualitative interviews showed high levels of acceptability of the program. CONCLUSIONS: The tested home-based rehabilitation program with health coaching was feasible, highly acceptable, showed a high degree of adherence, and improved self-management abilities. This study offers seminal information for home-based rehabilitation programs to design alternative options of rehabilitation to individuals with COPD that cannot attend to the well-established center-based pulmonary rehabilitation. (ClinicalTrials.gov registration NCT02557178.)
“What Matters to Me”: What pediatric stem cell transplant patients want their providers to know
McCarthy, Sarah , Tarquini, Sarah, Metcalf, Brittany, Pickard, Lucy, Greenzang, Katie A. , Mack, Jennifer W. , McCarthy, Sarah R. , McCarthy, Sarah R , McCarthy, Sarah R.

Mayo Clinic

Journal of Psychosocial Oncology | April 26, 2021 | Volume: 39 | Issue: 4 | Pages: 586-593

10.1080/07347332.2021.1906376 | PMID 33900895 Get It